Saphris

OBJECTIVE To assess clinical features of therapeutic efficacy and tolerability of asenapine (saphris) in stopping acute psychotic… Expand

The causes and origins of pica remain unknown and are the source of speculation and heated debate. Bariatric surgery patients are… Expand

To the Editor: Asenapine, marketed as Saphris, is a relatively new psychopharmaceutical agent approved in 2009 for the treatment… Expand

Asenapine was approved by the Food and Drug Administration (FDA) in 2009. This article reviews clinically significant aspects of… Expand

T he US health system is under reform. More than ever, busy practitioners need help in prescribing drugs more knowledgeably and… Expand

FDA has issued a Safety Announcement warning that serious allergic reactions have been reported with the use of the antipsychotic… Expand

On August 14th, 2009, for the first time, the FDA has approved a psychotropic medication for two indications simultaneously… Expand

 

Antipsychotic agents Asenapine (Saphris—Schering) and iloperidone (Fanapt—Vanda) are new atypical antipsychotic agents that join… Expand

The U.S. Food and Drug Administration has approved Saphris tablets to treat adults with schizophrenia, and bipolar I disorder in… Expand